drugset / Trial / NCT05483491
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Phase 1
Recruiting
30 enrolled
Christian Hinrichs
Iovance Biotherapeutics, Inc. · collabNational Cancer Institute (NCI) · collab
NaSequentialOpen-labelTreatment
Summary
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.
Timeline
- Start
- 2022-09-26
- Primary completion
- 2026-09-01
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | T-Cell Therapy | Cell therapy | — | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 720000 iu/kg | Intravenous |